ANI Pharmaceuticals price target raised to $77 from $65 at Truist

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $77 from $65 but keeps a Hold rating on the shares after its Q2 earnings beat. The management boosted the product’s guide which also coincided with commentary heard from the competition, even though the company’s Iluvien market access challenges remain and generics performed inline, the analyst tells investors in a research note. Truist adds that the ANI valuation at 10-times EBITDA warrants a neutral stance.